口服Atogepant预防发作性偏头痛的2b/3期试验
这项双盲随机2b/3期试验在美国78个中心纳入834例发作性偏头痛成人,比较安慰剂与五种口服Atogepant剂量方案。12周内所有Atogepant剂量组每月偏头痛天数较基线的下降均显著优于安慰剂,安全性和耐受性良好,支持其进入3期开发。
要点
- 所有五种Atogepant剂量方案在12周内均显著减少每月偏头痛天数。
- 最常见治疗中出现的不良事件为恶心和乏力,严重不良事件均与治疗无关。
- 因不良事件停药率Atogepant组为5%(33/639),安慰剂组为3%(5/186)。
核心结论
- 口服Atogepant各剂量在12周内均较安慰剂显著减少每月偏头痛天数,且安全可耐受。
研究设计与样本
- 双盲随机2b/3期试验,2016年9月6日至2018年4月23日在美国78个学术和私人执业机构开展。
- 筛查1772人,随机834人,825人至少接受一剂研究药物:安慰剂186例,Atogepant 10mg每日一次93例、30mg每日一次183例、60mg每日一次186例、30mg每日两次86例、60mg每日两次91例。
- 入组标准为18-75岁、偏头痛病史≥1年且每月偏头痛4-14天。
- 主要疗效分析纳入795例,采用改良意向性治疗分析。
主要发现
- 最常见治疗中出现的不良事件为恶心(各Atogepant组范围5%[5/93]至12%[22/186],安慰剂5%[9/186])和乏力(1%[1/93]至10%[9/91],安慰剂3%[6/186])。
- 治疗相关不良事件发生率Atogepant组为18%(17/93)至26%(24/91),安慰剂组为16%(30/186)。
- 7例报告8起严重治疗中出现的不良事件,所有严重不良事件均与治疗无关。
关键数值与推荐
- 主要疗效终点为12周治疗期内每月偏头痛天数较基线的变化。
临床怎么用
- 口服Atogepant各剂量均可显著减少发作性偏头痛患者的每月偏头痛天数,支持其用于偏头痛预防治疗。
- 恶心和乏力是常见不良事件,因不良事件停药率Atogepant组为5%(33/639)、安慰剂组为3%(5/186)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atogepant is an orally administered, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist under investigation for treatment of migraine. We aimed to examine a range of oral doses for safety, tolerability, and efficacy for the preventive treatment of migraine. METHODS: In this double-blind, phase 2b/3 trial, adults (aged 18-75 years), with a history (≥1 year) of migraine and 4-14 migraine days per month, were randomly assigned 2:1:2:2:1:1 (by means of a sequence generated by the statistical programming department of the sponsor, and operationalised through an automated interactive web-based response system) to receive placebo or atogepant 10 mg once daily, 30 mg once daily, 60 mg once daily, 30 mg twice daily, or 60 mg twice daily, in matching capsules. Participants, site personnel, and all study sponsor personnel were masked to treatment allocations. The study was done in 78 academic and private practice settings in the USA. The primary outcome was change from baseline in monthly migraine days across 12 weeks of treatment using a modified intention-to-treat approach. The overall type I error rate for multiple comparisons across active treatment doses was controlled at the 0·05 level by means of a graphic approach. The main outcomes to assess safety and tolerability were adverse event recordings. The trial is registered with ClinicalTrials.gov, NCT02848326 and is completed. FINDINGS: Between Sept 6, 2016, and April 23, 2018, of 1772 individuals screened, 834 were randomly assigned and 825 received one dose or more of study medication: 186 received placebo, 93 atogepant 10 mg once daily, 183 atogepant 30 mg once daily, 186 atogepant 60 mg once daily, 86 atogepant 30 mg twice daily, and 91 atogepant 60 mg twice daily. Overall, 714 (87%) of 825 participants were female, 628 (76%) were white, median migraine duration was 17·5 years (IQR 10·0-28·0), and 232 (28%) had previously used preventive treatment. The primary efficacy analysis included 795 patients: 178 received placebo, 92 atogepant 10 mg once daily, 182 atogepant 30 mg once daily, 177 atogepant 60 mg once daily, 79 atogepant 30 mg twice daily, and 87 atogepant 60 mg twice daily. Across the 12-week treatment period, all five atogepant groups showed significant least-squares mean (SE) change from baseline in mean monthly migraine days versus placebo: atogepant 10 mg once daily -4·0 (0·3; p=0·024), 30 mg once daily -3·8 (0·2; p=0·039), 60 mg once daily -3·6 (0·2; p=0·039), 30 mg twice daily -4·2 (0·4; p=0·0034), and 60 mg twice daily -4·1 (0·3; p=0·0031); placebo -2·9 (0·2). The most common treatment-emergent adverse events (TEAEs) across all groups were nausea (range 5% [5/93] for 10 mg once daily to 12% [22/186] for 60 mg once daily vs 5% [9/186] for placebo) and fatigue (1% [1/93] for 10 mg once daily to 10% [9/91] for 60 mg twice daily vs 3% [6/186] for placebo). Treatment-related TEAE frequency ranged from 18% (17/93) for 10 mg once daily to 26% (24/91) for 60 mg twice daily, versus 16% (30/186) for placebo. Seven participants reported a total of eight serious TEAEs (two participants each in the placebo, 30 mg once-daily, and 60 mg once-daily groups, and one participant in the 10 mg once-daily group). TEAEs leading to discontinuation were reported in 33 (5%) of 639 atogepant participants and 5 (3%) of 186 of those randomised to placebo. All serious TEAEs were unrelated to treatment. INTERPRETATION: All doses of oral atogepant were associated with a significant decrease in monthly migraine days over 12 weeks compared with placebo. Atogepant was safe and well tolerated over 12 weeks, supporting its phase 3 development for the preventive treatment of migraine. FUNDING: Allergan (before its acquisition by AbbVie).
引用
- Goadsby PJ, Dodick DW, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020. PMID: 32822633. doi:10.1016/S1474-4422(20)30234-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。